Akums commissions new manufacturing facility for Lyophilized and Sterile dosage

The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products

Lonza outlines strategy, new organizational structure and guidance

The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities

Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million

This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape

Laurus Labs invests in Laurus Bio

Siegfried opens global R&D Center for Drug Substances in Switzerland

The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth

CPHI India reports surge in exhibitor numbers

Modernization and supply chain diversity drive new growth

Shilpa Medicare Q2 FY25 consolidated PAT up 1,008% at Rs. 18 Cr

Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2

Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds

Hikal Q2 FY25 revenue stood at Rs. 453 Cr

In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%

Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr

For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore